Phase 2 N=9 Combination of Insulin Sensitizer and Leptin as Treatment for the HAART -Induced Metabolic Syndrome
HIV Lipodystrophy
Primary: Insulin Resistance (HOMA Index) — 1.6; 1.8 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,692 Efficacy, Safety and Tolerability of Aclidinium Bromide/Formoterol Fumarate Compared With Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease
Primary: Change From Baseline in 1-hour Morning Post-dose Forced Expiratory Volume in One Second (FEV1) — 0.247; 0.226; 0.139; 0.165 Liters — p=<0.0001
Phase 2 N=29 Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers
Cervical Cancer · Oropharyngeal Cancer · Vaginal Cancer
Primary: Number of Participants With an Objective Clinical Response — 3; 2; 2; 0 Participants
Phase 3 N=190 Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis
Eosinophilic Esophagitis
Primary: Number of Participants With Treatment-emergent Adverse Events (AEs), Serious AEs, or Discontinuation Due to AEs — 177; 38; 63; 0 participants
Phase 3 N=571 Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic Therapy
Actinic Keratosis
Primary: Percentage of Participants With Complete Response 12 Weeks After the Last Photodynamic Therapy (PDT), ITT — 17.1; 78.2; 64.2 percentage of patients — p=0.0000
Phase 2 N=659 A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Percentage of Participants Achieving Objective Response (ORR) Per Response Evaluation Criteria In Solid Tumors (RECIST) Version (v) 1.1 as Assessed by Independent Review…
Phase 4 N=175 Long-term Follow-up of Fingolimod Phase II Study Patients
Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis
Primary: Change From Baseline (BL) in Expanded Disability Status Scale (EDSS) — 0.58; 1.17 score on a scale — p=0.0155
Phase 2 N=32 Study of Triheptanoin for Treatment of Long-Chain Fatty Acid Oxidation Disorder
Very Long-chain acylCoA Dehydrogenase (VLCAD) Deficiency · Carnitine Palmitoyltransferase 2 (CPT2) Deficiency · Mitochondrial Trifunctional Protein (TFP) Deficiency
Primary: Energy Expenditure — -73; 107 kcal/day
N/A N=1,369 Computer Automation for Diagnosis and Management of Childhood Type 2 Diabetes
Type 2 Diabetes
Primary: Number of Children With Documented Risk Factors for Type 2 Diabetes — 283; 282 Participants
N/A N=2,237 Child Health Improvement Through Computer Automation (CHICA) Highlighting Study
Physician Behavior
Primary: The Number of Prompts That Were Responded to — 672; 712 Participants
Phase 1 N=24 Vitamin D and Severe Asthma Exacerbations
Asthma
Primary: Number of Participants With Sufficient Vitamin D Levels (≥30 ng/ml) After 8 Weeks of Supplementation — 8; 6; 4 participants
Phase 2 N=31 Pilot Study of VVD-101 for the Treatment of Delayed Alcohol-Induced Headaches
Delayed Alcohol Induced Headache
Primary: Headache Severity 2 Hours Post Treatment — 2.18; 2.09; 0.85; 1.17 units on a scale
N/A N=230 The Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity
Dentin Sensitivity
Primary: Change From Baseline in Schiff Sensitivity Score on Day 3 — -0.96; -0.77 Score on a scale — p=0.1575
N/A N=212 Ultrasound Guided Vascular Access in Pediatric Intensive Care Patients
Critical Illness
Primary: Central Line Placement Success — 82; 108 participants — p=<0.001
Phase 2 N=10 Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss Syndrome
Churg Strauss Syndrome
Primary: Number of Participants With Indicated Side Effects — 3; 1; 0; 1 Participants